阿里健康今日盘中大涨5.17%，引起了市场的广泛关注。
消息面上，创新药首发平台效应持续发酵。近期，恒瑞医药的1类创新药“瑞鸣”及扬子江药业的1类新药“泰妥妥”同日选择在阿里健康平台全网首发，随后九典制药旗下的“久悦洛索洛芬钠凝胶贴膏”亦在该平台首发。多款新药密集上线，强化了阿里健康作为“新特药首发阵地”的平台定位，验证了其在创新药商业化环节的渠道价值与数字化服务能力。此外，公司管理层已明确2027财年收入同比增长10%至15%的指引，其中创新药品类被视为核心增长驱动。
与此同时，医药电商板块整体走强，为阿里健康的股价表现提供了板块层面的支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.